-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Imago BioSciences (NASDAQ:IMGO) Shares Gap Down to $15.29
Imago BioSciences (NASDAQ:IMGO) Shares Gap Down to $15.29
Shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) gapped down before the market opened on Friday . The stock had previously closed at $15.29, but opened at $14.61. Imago BioSciences shares last traded at $15.26, with a volume of 105 shares trading hands.
Analyst Upgrades and Downgrades
Separately, HC Wainwright cut their price objective on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Stock Performance
The company's 50-day moving average is $16.20 and its 200 day moving average is $16.33. The company has a market capitalization of $507.79 million, a PE ratio of -8.46 and a beta of 2.48.
Insider Activity at Imago BioSciences
In related news, insider Jennifer Peppe sold 5,598 shares of the stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $19.41, for a total transaction of $108,657.18. Following the sale, the insider now directly owns 148,809 shares of the company's stock, valued at approximately $2,888,382.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 8,168 shares of company stock valued at $155,402. 14.90% of the stock is owned by insiders.Hedge Funds Weigh In On Imago BioSciences
Several hedge funds and other institutional investors have recently bought and sold shares of IMGO. Ensign Peak Advisors Inc bought a new position in Imago BioSciences during the 4th quarter valued at about $593,000. Citadel Advisors LLC lifted its stake in Imago BioSciences by 20.1% during the 4th quarter. Citadel Advisors LLC now owns 2,452,926 shares of the company's stock valued at $57,271,000 after acquiring an additional 410,487 shares during the period. Woodline Partners LP lifted its stake in Imago BioSciences by 101.9% during the 4th quarter. Woodline Partners LP now owns 848,129 shares of the company's stock valued at $20,109,000 after acquiring an additional 428,127 shares during the period. Emerald Advisers LLC lifted its stake in Imago BioSciences by 7.0% during the 1st quarter. Emerald Advisers LLC now owns 616,368 shares of the company's stock valued at $11,877,000 after acquiring an additional 40,209 shares during the period. Finally, New York State Common Retirement Fund lifted its stake in Imago BioSciences by 106.6% during the 1st quarter. New York State Common Retirement Fund now owns 13,391 shares of the company's stock valued at $258,000 after acquiring an additional 6,909 shares during the period. Institutional investors own 99.50% of the company's stock.
Imago BioSciences Company Profile
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
Recommended Stories
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) gapped down before the market opened on Friday . The stock had previously closed at $15.29, but opened at $14.61. Imago BioSciences shares last traded at $15.26, with a volume of 105 shares trading hands.
周五开盘前，Imago BioSciences，Inc.(纳斯达克代码：IMGO-GET Rating)的股价大幅下跌。该股此前收盘报15.29美元，开盘报14.61美元。Imago BioSciences的股票最新报15.26美元，成交量为105股。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Separately, HC Wainwright cut their price objective on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, August 16th.
另外，在8月16日(星期二)的一份研究报告中，HC Wainwright将Imago BioSciences的股票目标价从36.00美元下调至35.00美元，并对该股设定了“买入”评级。
Imago BioSciences Stock Performance
Imago BioSciences股票表现
The company's 50-day moving average is $16.20 and its 200 day moving average is $16.33. The company has a market capitalization of $507.79 million, a PE ratio of -8.46 and a beta of 2.48.
该公司的50日移动均线切入位在16.20美元，200日移动均线切入位在16.33美元。该公司市值为5.0779亿美元，市盈率为-8.46，贝塔系数为2.48。
Insider Activity at Imago BioSciences
Imago BioSciences的内部活动
Hedge Funds Weigh In On Imago BioSciences
对冲基金参与Imago BioSciences
Several hedge funds and other institutional investors have recently bought and sold shares of IMGO. Ensign Peak Advisors Inc bought a new position in Imago BioSciences during the 4th quarter valued at about $593,000. Citadel Advisors LLC lifted its stake in Imago BioSciences by 20.1% during the 4th quarter. Citadel Advisors LLC now owns 2,452,926 shares of the company's stock valued at $57,271,000 after acquiring an additional 410,487 shares during the period. Woodline Partners LP lifted its stake in Imago BioSciences by 101.9% during the 4th quarter. Woodline Partners LP now owns 848,129 shares of the company's stock valued at $20,109,000 after acquiring an additional 428,127 shares during the period. Emerald Advisers LLC lifted its stake in Imago BioSciences by 7.0% during the 1st quarter. Emerald Advisers LLC now owns 616,368 shares of the company's stock valued at $11,877,000 after acquiring an additional 40,209 shares during the period. Finally, New York State Common Retirement Fund lifted its stake in Imago BioSciences by 106.6% during the 1st quarter. New York State Common Retirement Fund now owns 13,391 shares of the company's stock valued at $258,000 after acquiring an additional 6,909 shares during the period. Institutional investors own 99.50% of the company's stock.
几家对冲基金和其他机构投资者最近买卖了IMGO的股票。Ensign Peak Advisors Inc.在第四季度购买了Imago BioSciences的一个新头寸，价值约593,000美元。Citadel Advisors LLC在第四季度将其在Imago BioSciences的持股比例提高了20.1%。Citadel Advisors LLC在此期间额外收购了410,487股，目前拥有2,452,926股该公司股票，价值57,271,000美元。第四季度，Woodline Partners LP将其在Imago BioSciences的持股比例提高了101.9%。Woodline Partners LP在此期间额外收购了428,127股票，现在拥有848,129股该公司的股票，价值20,109,000美元。Emerald Advisers LLC在第一季度将其在Imago BioSciences的持股增加了7.0%。Emerald Advisers LLC在此期间增持了40,209股，目前拥有616,368股该公司股票，价值11,877,000美元。最后，纽约州共同退休基金在第一季度将其在Imago BioSciences的持股增加了106.6%。纽约州共同退休基金现在拥有13,391股该公司的股票，价值258,000美元，在此期间又购买了6,909股。机构投资者持有该公司99.50%的股票。
Imago BioSciences Company Profile
Imago BioSciences公司简介
(Get Rating)
(获取评级)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
临床阶段生物制药公司Imago BioSciences，Inc.发现和开发了针对赖氨酸特异性脱甲基酶1(LSD1)的小分子产品候选产品，LSD1是一种用于生产骨髓中血细胞的酶。它的主要候选产品是Bomedemstat，正在进行第二阶段临床试验，用于治疗骨髓增生性肿瘤和慢性骨髓癌，如骨髓纤维化、原发性血小板增多症和真性红细胞增多症。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
- 免费获取StockNews.com关于Imago BioSciences(IMGO)的研究报告
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat：回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 让Paychex股票为您努力工作
- 利润下降对CarMax价值主张的挑战
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Imago BioSciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧